Forte Biosciences (FBRX) Interest Expenses (2016 - 2020)
Forte Biosciences (FBRX) posted quarterly Interest Expenses of $43.7 million for Q1 2026, up 5211.44% year-over-year from $822000.0 in Q1 2025, and up 101434.88% quarter-over-quarter from $43000.0 in Q4 2025.
Powered by 
Analysis
Forte Biosciences (FBRX) Interest Expenses (2016 - 2020) Analysis & Trends
Forte Biosciences (FBRX) has reported Interest Expenses for 11 consecutive years, with $43.7 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Interest Expenses rose 5211.44% year-over-year to $43.7 million; the TTM figure through Mar 2026 stood at $43.7 million (up 5211.44% YoY), while the FY2025 annual figure was $47.1 million, up 92.12% from the prior year.
- Interest Expenses advanced to $43.7 million in Q1 2026 per FBRX's latest filing, from $43000.0 in the prior quarter.
- Across five years, Interest Expenses topped out at $43.7 million in Q1 2026 and bottomed at $5000.0 in Q3 2023.
- Historically, Interest Expenses has averaged $4.5 million across 5 years, with a median of $81000.0 in 2024.
- Annual changes were most pronounced in 2022 — Interest Expenses sank 99.06% — and 2025, when it soared 62082.14%.
- Forte Biosciences' Interest Expenses stood at $65000.0 in 2022, then tumbled by 53.85% to $30000.0 in 2023, then surged by 170.0% to $81000.0 in 2024, then tumbled by 46.91% to $43000.0 in 2025, then soared by 101434.88% to $43.7 million in 2026.
- Business Quant data shows FBRX's Interest Expenses at $43.7 million in Q1 2026, $43000.0 in Q4 2025, and $17.4 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.78 Bn | 130.92 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.50 Bn | 77.51 Bn | 3.93 Bn | 11.00 Mn |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn | -1.00 Mn |
| 4 | Moderna | 58.06 Bn | 52.92 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.04 Bn | 44.04 Bn | - | 23.78 Mn |
| 6 | BeOne Medicines | 40.04 Bn | 34.94 Bn | 1.53 Bn | 39.74 Mn |
| 7 | Alnylam Pharmaceuticals | 35.45 Bn | 32.14 Bn | 992.69 Mn | 82.05 Mn |
| 8 | Royalty Pharma | 28.41 Bn | 27.57 Bn | - | 93.62 Mn |
| 9 | Insmed | 27.42 Bn | 26.26 Bn | 358.27 Mn | 20.27 Mn |
| 10 | Forte Biosciences | 1.58 Bn | 1.23 Bn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2020 | 756,000.00 |
| Dec 31, 2019 | 330,000.00 |
| Sep 30, 2019 | 1.97 Mn |
| Jun 30, 2019 | 764,000.00 |
| Mar 31, 2019 | 754,000.00 |
| Dec 31, 2018 | 746,000.00 |
| Sep 30, 2018 | 742,000.00 |
| Jun 30, 2018 | 1.09 Mn |
| Mar 31, 2018 | 349,000.00 |
| Dec 31, 2017 | 391,000.00 |
| Sep 30, 2017 | 430,000.00 |
| Jun 30, 2017 | 495,000.00 |
| Mar 31, 2017 | 616,000.00 |
| Dec 31, 2016 | 533,000.00 |
| Sep 30, 2016 | 511,000.00 |
| Jun 30, 2016 | 505,000.00 |
| Mar 31, 2016 | 503,000.00 |